October 2015 - Cancer Currents Blog
- Patients with Advanced Cancer May Benefit from Discussing Prognosis with Physicians
Patients with advanced cancer may benefit from having discussions about their prognoses with their physicians.
- Study Identifies New Opportunities for Targeted Immunotherapy
A team of NCI researchers has reported that several types of gastrointestinal cancer have tumor-specific mutations that can be recognized by the immune system, thereby offering a new therapeutic opportunity for patients with these tumors.
- In Triple-Negative Breast Cancer, Targeting an Addiction
A new approach to disrupting genes that promote the development and spread of tumors may hold promise for treating an aggressive and difficult-to-treat type of breast cancer.
- Bringing Cancer Research to the Public: NCI’s Networks and Programs
A number of NCI programs and networks are the foundation of the National Cancer Program and play a critical role in promoting progress.
- Long-Term Study Finds No Increased Risk of Miscarriage after HPV Vaccination
Women in a clinical trial who became pregnant after vaccination with a bivalent human papillomavirus (HPV) vaccine did not have an increased risk of miscarriage.
- FDA Approves Combination Drug for Patients with Advanced Colorectal Cancer
The FDA has approved a single drug that combines trifluridine and tipiracil to treat patients with metastatic colorectal cancer whose disease progressed after standard treatment.
- Progress against Cancer: The Role of Basic Science
Acting NCI Director Doug Lowy, M.D., discusses the critical contribution of basic science in fostering progress against cancer.
- NCI’s Steven Rosenberg Wins Service to America Medal
The Partnership for Public Service has awarded Steven A. Rosenberg, M.D., of NCI's Center for Cancer Research, with its highest 2015 Samuel J. Heyman Service to America Medal, or Sammie.
- Persistence of Genetic Mutations after Chemotherapy Linked to Poor Outcomes in Some Patients with AML
The persistence of genetic mutations in some patients with acute myeloid leukemia may allow physicians to better classify their risk of recurrence.